JAK inhibitors should be last-resort for high-risk patients: TGA safety alert
But Melbourne rheumatologist Professor Rachelle Buchbinder stressed patients may still wish to continue treatment.
The TGA has issued a safety warning over Janus kinase inhibitor use in high-risk patients with chronic inflammatory conditions after a post-market study showed an increased risk of death, cancer and MI.
Over-65s with a history of smoking or increased risk of major cardiovascular problems or cancer are now advised against using the drug class “unless there are no suitable treatment alternatives” for their condition.
